MANKIND PHARMA
Back to Income Statement
|
MANKIND PHARMA Last 5 Year Consolidated Net Profit History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Consolidated Net Profit | ₹1,282 Cr | ₹1,433 Cr | ₹127 Cr | ₹10,304 Cr | ₹579 Cr |
What is the latest Consolidated Net Profit of MANKIND PHARMA ?
Year | Consolidated Net Profit |
---|---|
Mar2024 | ₹1,282 Cr |
Mar2023 | ₹1,433 Cr |
Mar2022 | ₹127 Cr |
Mar2021 | ₹10,304 Cr |
Mar2020 | ₹579 Cr |
How is Consolidated Net Profit of MANKIND PHARMA Trending?
Years | Consolidated Net Profit | % Change | |
---|---|---|---|
Mar2024 | ₹1,282 Cr | -10.58 | |
Mar2023 | ₹1,433 Cr | 1,032.80 | |
Mar2022 | ₹127 Cr | -98.77 | |
Mar2021 | ₹10,304 Cr | 1,681.10 | |
Mar2020 | ₹579 Cr | - |
Compare Consolidated Net Profit of peers of MANKIND PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MANKIND PHARMA | ₹98,303.1 Cr | 1.1% | -7% | 9.7% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹405,176.0 Cr | -0.3% | -2.9% | 11.5% | Stock Analytics | |
DIVIS LABORATORIES | ₹177,076.0 Cr | 0.7% | 7.4% | 48.1% | Stock Analytics | |
CIPLA | ₹121,592.0 Cr | -0.1% | 0.2% | -2.1% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹113,615.0 Cr | 3.2% | 10.3% | 11.7% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹110,024.0 Cr | 2.3% | -0.5% | 13.8% | Stock Analytics |
MANKIND PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MANKIND PHARMA | 1.1% |
-7% |
9.7% |
SENSEX | -1.3% |
-0.3% |
5.8% |
You may also like the below Video Courses